Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Katharina Seitz

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Urologia Internationalis|July 31, 2024
Refluxing versus Non-Refluxing Ureteric Implantation in Continent Cutaneous Urinary Diversion: A Propensity-Scored Comparison regarding Long-Term Renal, Metabolic, and Functional Outcomes of Patients with Ileocecal PouchMarcel Schwinger, Anna Katharina Seitz, Hubert Kübler, et al.
Urologia Internationalis|August 18, 2024
A Propensity Score-Based Comparison regarding Renal, Functional, and Surgical Outcome of Continent Cutaneous Urinary Diversions in Patients with Benign Chronic Bladder Diseases and Patients with Bladder CancerVincent Scheper, Anna Katharina Seitz, Hubert Kübler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 28, 2019
False-negative <sup>18</sup>F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptakePhilipp E Hartrampf, Anna Katharina Seitz, Markus Krebs, et al.
Urologic Oncology|February 4, 2023
Preliminary results regarding automated identification of patients with a limited six-month survival prognosis using nursing assessment in uro-oncology patientsCarmen Roch, Julian Alexander Kielkopf, Ulrich Stefenelli, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 18, 2020
Prognostic implications of dual tracer PET/CT: PSMA ligand and [<sup>18</sup>F]FDG PET/CT in patients undergoing [<sup>177</sup>Lu]PSMA radioligand therapyKerstin Michalski, Juri Ruf, Christian Goetz, et al.
World Journal of Urology|May 28, 2013
The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancerThomas Horn, Barbara Ladwein, Tobias Maurer, et al.
Biomedicines|November 21, 2020
Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation TherapyJoachim Brumberg, Melanie Beckl, Alexander Dierks, et al.
Urologia Internationalis|April 28, 2026
Routine Retrograde Conduitography after Radical Cystectomy for Bladder Cancer: Diagnostic Yield and Clinical ImpactVincent Scheper, Lea Berninger, Marcel Schwinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 2, 2026
Overall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World AnalysisNatalie Hasenauer, Charlotte Probst, Wiebke Schloetelburg, et al.
Cancers|September 10, 2021
Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient OutcomePhilipp E Hartrampf, Constantin Lapa, Sebastian E Serfling, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Urologia Internationalis|July 31, 2024
Refluxing versus Non-Refluxing Ureteric Implantation in Continent Cutaneous Urinary Diversion: A Propensity-Scored Comparison regarding Long-Term Renal, Metabolic, and Functional Outcomes of Patients with Ileocecal PouchMarcel Schwinger, Anna Katharina Seitz, Hubert Kübler, et al.
Urologia Internationalis|August 18, 2024
A Propensity Score-Based Comparison regarding Renal, Functional, and Surgical Outcome of Continent Cutaneous Urinary Diversions in Patients with Benign Chronic Bladder Diseases and Patients with Bladder CancerVincent Scheper, Anna Katharina Seitz, Hubert Kübler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 28, 2019
False-negative <sup>18</sup>F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptakePhilipp E Hartrampf, Anna Katharina Seitz, Markus Krebs, et al.
Urologic Oncology|February 4, 2023
Preliminary results regarding automated identification of patients with a limited six-month survival prognosis using nursing assessment in uro-oncology patientsCarmen Roch, Julian Alexander Kielkopf, Ulrich Stefenelli, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 18, 2020
Prognostic implications of dual tracer PET/CT: PSMA ligand and [<sup>18</sup>F]FDG PET/CT in patients undergoing [<sup>177</sup>Lu]PSMA radioligand therapyKerstin Michalski, Juri Ruf, Christian Goetz, et al.
World Journal of Urology|May 28, 2013
The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancerThomas Horn, Barbara Ladwein, Tobias Maurer, et al.
Biomedicines|November 21, 2020
Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation TherapyJoachim Brumberg, Melanie Beckl, Alexander Dierks, et al.
Urologia Internationalis|April 28, 2026
Routine Retrograde Conduitography after Radical Cystectomy for Bladder Cancer: Diagnostic Yield and Clinical ImpactVincent Scheper, Lea Berninger, Marcel Schwinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 2, 2026
Overall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World AnalysisNatalie Hasenauer, Charlotte Probst, Wiebke Schloetelburg, et al.
Cancers|September 10, 2021
Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient OutcomePhilipp E Hartrampf, Constantin Lapa, Sebastian E Serfling, et al.
Pageof 4